Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the Company is scheduled to present new data on its allogeneic CRISPR-based CAR-T programs at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 16, 2018 in Chicago, IL.
Presentation: Allogeneic chimeric antigen receptor T cells targeting B cell maturation antigen
Session: Adoptive Cell Therapy 1
Time and Date: 8:00 AM – 12:00 PM CDT, Monday, April 16, 2018
Location: McCormick Place South (Level 3), Exhibit Hall A, Section 24, Poster 1540
Presentation: Allogeneic CRISPR engineered anti CD70 CAR T cells demonstrate potent preclinical activity against both solid and hematological cancer cells
Session: Adoptive Cell Therapy 2
Time and Date: 1:00 PM - 5:00 PM CDT, Monday, April 16, 2018
Location: McCormick Place South (Level 3), Exhibit Hall A, Section 24, Poster 2551
Following presentation at the meeting, the posters will be available on CRISPR Therapeutics’ website at http://www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
CONTACTS
CRISPR Therapeutics
Investors:
Chris Erdman
617-307-7227
[email protected]
or
Chris Brinzey
Westwicke Partners
339-970-2843
[email protected]
Media:
Jennifer Paganelli
WCG for CRISPR
347-658-8290
[email protected]
